Last checked at 5 Jul 2019 07:00
Creo Medical Group plc
("Creo" or the "Company")
Institute of Physics Award &
Royal Academy of Engineering Visiting Professor appointment
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that Chris Hancock, founder of Creo and Chief Technology Officer, has been awarded the Katharine Burr Blodgett Medal and Prize for 2019 by the Institute of Physics ("IOP") and has been appointed as a Visiting Professor by the Royal Academy of Engineering.
Katharine Burr Blodgett Medal and Prize
The Katharine Burr Blodgett Medal, introduced by the IOP in 2008, is awarded for outstanding and sustained contributions to the organisation or application of physics in an industrial or commercial context.
The 2019 Medal and Prize was awarded to Professor Hancock "for designing and patenting an electro-surgery platform enabling microwave and bi-polar radio frequency to be delivered to a range of miniature endoscopic devices to treat lesions in the gastrointestinal (GI) tract."
For the full citation: http://www.iop.org/about/awards/gold/burr-blodgett/medallists/page_72859.html
Visiting Professor appointment
In addition, The Royal Academy of Engineering has appointed Chris Hancock as a Visiting Professor to University College London to deliver face-to-face teaching and mentoring for three years. Engineering undergraduates will benefit from an enhanced understanding of the role of engineering and the way it is practised, along with its challenges and demands and the programme also enables engineers to contribute to postgraduate teaching and curriculum development, to continue the impact of the scheme beyond the length of the appointment.
About Chris Hancock
Chris has over 20 years of experience in medical device development including four years at Gyrus Group plc in his role as Senior Engineer. Chris holds a personal Chair in the Medical Microwave Systems Research Group at Bangor University. Chris is a Fellow of the Institute of Physics, a Chartered Physicist, Fellow of the Institute of Engineering and Technology, a Chartered Engineer and a Senior Member of the IEEE. He is a named inventor and lead author on over 500 patents/patent applications and journal publications and was recently named in the Sunday Times Maserati 100, its annual list of inspiring entrepreneurs.
Chris Hancock, Chief Technology Officer and Founder of Creo Medical, said: "It is a great honour to receive the Katharine Burr Blodgett Medal and Prize from the Institute of Physics, and I am delighted to have been appointed as a Royal Academy of Engineering Visiting Professor to UCL. I am incredibly grateful for the support that the team at Creo have provided as we have developed a platform to apply microwave and RF energy to surgical endoscopy and bring this to fruition in a commercial suite of products. Most important of all is that these combined efforts have created the first of those products which is already improving patient outcomes around the world."
Creo was also included within Wales Business Insider's list of the 'Most Exciting Companies in Wales', which highlights 50 innovative, fast-moving Welsh businesses. The Most Exciting Companies list was published in the July 2019 edition of the magazine.
Creo Medical Group plc |
|
Richard Rees (CFO) | +44 (0)129 160 6005 |
|
|
Cenkos Securities | +44 (0)20 7397 8900 |
Stephen Keys / Mark Connelly (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7515 909 238 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com